<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919217</url>
  </required_header>
  <id_info>
    <org_study_id>08.0172</org_study_id>
    <nct_id>NCT00919217</nct_id>
  </id_info>
  <brief_title>Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms</brief_title>
  <official_title>Exploratory Study on the Timing of MS Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting&#xD;
      multiple sclerosis (RR-MS) symptoms are affected by various factors including stress,&#xD;
      hormonal cycles, illness and missed medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluctuations in MS symptoms in women with RR-MS might be affected by a variety of factors. To&#xD;
      determine which factors are important, we are asking subjects to fill out a diary and&#xD;
      calendar on a daily basis for 90 days. After an initial instructional meeting over the phone,&#xD;
      the materials are filled out at home and returned monthly via postage-paid envelopes provided&#xD;
      by the study. Compensation ($10 gift card) is sent after each monthly diary is received. The&#xD;
      diary includes a list of symptoms and a rank scale for the women to show subtle changes in MS&#xD;
      symptoms. The calendar allows the subject to denote additional factors such as stress,&#xD;
      hormonal cycles, illnesses or immunizations and changed or missed medications. We anticipate&#xD;
      that statistical analysis will reveal which of these factors affect women with&#xD;
      relapsing-remitting multiple sclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of days with appearance or worsening of symptoms</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>timing of appearance or worsening of symptoms</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Relapsing-remitting multiple sclerosis</arm_group_label>
    <description>Females with relapsing-remitting multiple sclerosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Females with relapsing-remitting multiple sclerosis, not menopausal, neither pregnant nor&#xD;
        nursing, not treated with steroids in the last 30 days and not on experimental medications&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  females&#xD;
&#xD;
          -  diagnosed with relapsing-remitting multiple sclerosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  no diagnosis of relapsing-remitting MS&#xD;
&#xD;
          -  diagnosis of any other autoimmune disease or fibromyalgia&#xD;
&#xD;
          -  peri-, post-, or surgically menopausal&#xD;
&#xD;
          -  pregnant within past year or nursing&#xD;
&#xD;
          -  history of chemotherapy&#xD;
&#xD;
          -  on experimental medications&#xD;
&#xD;
          -  treatment with steroids in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Corbitt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville, Dept. Biology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Corbitt, PhD</last_name>
    <phone>502-852-3915</phone>
    <email>cynthia.corbitt@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville (recruiting nationwide)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Corbitt, PhD</last_name>
      <phone>502-852-3915</phone>
      <email>cynthia.corbitt@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Corbitt, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 10, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Cynthia Corbitt</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>Relapsing-remitting multiple sclerosis</keyword>
  <keyword>RR-MS</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

